37 results on '"Ulcerative colitis -- Care and treatment"'
Search Results
2. Safety and Efficacy of Subcutaneous Entyvio(r) (Vedolizumab) Sustained During Long-term Maintenance Therapy in Adults with Moderately to Severely Active Ulcerative Colitis
3. Investigational Subcutaneous Formulation of Vedolizumab Achieves and Maintains Clinical Remission and Mucosal Healing at Week 52 in Patients with Moderately to Severely Active Ulcerative Colitis
4. Protagonist Therapeutics Reports Second Quarter 2018 Financial Results
5. New Phase 3 Data Show Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Ulcerative Colitis
6. DDW 2018: Patients with Moderate-to-Severe Ulcerative Colitis Achieved Clinical and Endoscopic Remission with Mirikizumab in Phase 2 Trial
7. Lilly to Showcase New Data at Digestive Disease Week 2018 for Mirikizumab in Moderate-to- Severe Ulcerative Colitis
8. Sandoz receives positive CHMP opinion for proposed biosimilar adalimumab
9. Lilly to Showcase New Data at Digestive Disease Week 2018 for Mirikizumab in Moderate-to-Severe Ulcerative Colitis
10. European Medicine Agency new product details:Zessly
11. Arena Pharmaceuticals Reports Positive Phase 2 Results from the OASIS Trial for Etrasimod in Patients with Ulcerative Colitis
12. Pfizer Announces Favorable Outcome of FDA Advisory Committee Meeting on XELJANZ(r) (tofacitinib) for Moderately to Severely Active Ulcerative Colitis
13. OTEZLA(r) (Apremilast) Phase II Data Showed Clinically Meaningful Improvements in Patients with Active Ulcerative Colitis
14. OTEZLA(r) (Apremilast) Phase II Data Showed Clinically Meaningful Improvements in Patients with Active Ulcerative Colitis
15. OTEZLA(r) (Apremilast) Phase II Data Showed Clinically Meaningful Improvements in Patients with Active Ulcerative Colitis
16. OTEZLA (Apremilast) Phase II Data Showed Clinically Meaningful Improvements in Patients with Active Ulcerative Colitis
17. OTEZLA(r) (Apremilast) Phase II Data Showed Clinically Meaningful Improvements in Patients with Active Ulcerative Colitis
18. OTEZLA(r) (Apremilast) Phase II Data Showed Clinically Meaningful Improvements in Patients with Active Ulcerative Colitis
19. Seres Therapeutics Reports SER-287 Phase 1b Microbiome Analyses that Provide Mechanistic Support for Clinical Efficacy in Ulcerative Colitis
20. ABIVAX to Initiate Long-Term Extension Study of ABX464 in Patients with Ulcerative Colitis
21. Asana Medical, Inc. Announces Corporate Name Change to Regentys
22. Pfizer Announces FDA Accepts Supplemental New Drug Application for XELJANZ(r) (tofacitinib citrate) for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis
23. Pfizer Announces FDA Accepts Supplemental New Drug Application for XELJANZ(r) (tofacitinib citrate) for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis
24. InDex Pharmaceuticals Enrolls First Patient in the Phase IIb Study CONDUCT With Cobitolimod
25. The Lancet Publishes Phase 2 Results from Shire's Investigational Anti-MAdCAM Antibody Showing Significantly Increased Remission Rates in Patients with Moderate-to-Severe Ulcerative Colitis
26. The Lancet Publishes Phase 2 Results from Shire's Investigational Anti-MAdCAM Antibody Showing Significantly Increased Remission Rates in Patients with Moderate-to-Severe Ulcerative Colitis
27. The Lancet Publishes Phase 2 Results from Shire's Investigational Anti-MAdCAM Antibody Showing Significantly Increased Remission Rates in Patients with Moderate-to-Severe Ulcerative Colitis
28. Phase 3 OCTAVE Studies of Oral Tofacitinib in Ulcerative Colitis Results Published in The New England Journal of Medicine
29. Yoga Helps Patients with Ulcerative Colitis
30. European Commission Approves AMGEVITA (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases
31. Amgevita
32. Solymbic
33. Amgevita
34. Solymbic
35. Gilead Terminates Phase 2|3 Study of GS-5745 in Patients With Ulcerative Colitis
36. Gilead Terminates Phase 2/3 Study of GS-5745 in Patients With Ulcerative Colitis
37. Pfizer Announces Positive Top-Line Results from Pivotal Phase 3 Maintenance Trial of Oral XELJANZ (Tofacitinib Citrate) in Ulcerative Colitis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.